Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/14/2022 | $25.00 | Buy | HC Wainwright & Co. |
| 12/23/2021 | $25.00 | Overweight | Cantor Fitzgerald |
| 11/1/2021 | $24.00 | Outperform | SVB Leerink |
| 9/13/2021 | $30.00 | Buy | Laidlaw |
| 8/25/2021 | $26.00 | Buy | B. Riley Securities |
| 8/13/2021 | $33.00 → $30.00 | Buy | Chardan Capital |
SCHEDULE 13G/A - Vincerx Pharma, Inc. (0001796129) (Subject)
DEFA14A - Vincerx Pharma, Inc. (0001796129) (Filer)
DEFA14A - Vincerx Pharma, Inc. (0001796129) (Filer)
Revised Potential Distribution Range of $0.03 to $0.07 per sharebased on current estimates and assumptions Failure to approve Dissolution Proposal on a timely basis will result in continued operating costs and further reduce or eliminate any potential distributions to stockholders SAN MATEO, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (OTC:VINC) today announced that the re-convened Special Meeting of Stockholders to consider a proposal to approve the liquidation and dissolution of Vincerx (the "Dissolution Proposal"), which was originally scheduled for earlier today, has again been adjourned, this time until 10:00 a.m., Pacific time, on August 27, 2025 via li
Potential Distribution Range of $0.04 to $0.08 per share of outstanding stock based on current estimates and assumptions, including timely approval of Distribution Proposal Failure to approve Dissolution Proposal will reduce or eliminate any potential distributions to stockholders SAN MATEO, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (OTC:VINC) today announced updated information regarding the Special Meeting of Stockholders of the Company (the "Special Meeting") to consider the proposal to approve the dissolution and liquidation of the Company pursuant to the Plan of Liquidation and Dissolution (the "Dissolution Proposal"). The Special Meeting was adjourned to 10:0
SAN MATEO, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (OTC:VINC) today announced that the Special Meeting of Stockholders to consider a proposal to approve the liquidation and dissolution of Vincerx (the "Dissolution Proposal"), which was originally scheduled for earlier today, has been adjourned until 10:00 a.m., Pacific time, on July 16, 2025 via live audio webcast at www.virtualshareholdermeeting.com/VINC2025SM2. The adjournment will allow Vincerx more time to solicit the votes needed to approve the Dissolution Proposal. Vincerx is urging ALL stockholders to vote IMMEDIATELY FOR the Dissolution Proposal. Vincerx's board of directors unanimously recommends that stoc
3 - Vincerx Pharma, Inc. (0001796129) (Issuer)
4 - Vincerx Pharma, Inc. (0001796129) (Issuer)
4 - Vincerx Pharma, Inc. (0001796129) (Issuer)
HC Wainwright & Co. initiated coverage of Vincerx Pharma with a rating of Buy and set a new price target of $25.00
Cantor Fitzgerald initiated coverage of Vincerx Pharma with a rating of Overweight and set a new price target of $25.00
SVB Leerink initiated coverage of Vincerx Pharma with a rating of Outperform and set a new price target of $24.00
SC 13G - Vincerx Pharma, Inc. (0001796129) (Subject)
SC 13G/A - Vincerx Pharma, Inc. (0001796129) (Subject)
SC 13G/A - Vincerx Pharma, Inc. (0001796129) (Subject)